SEATTLE--(Business Wire / Korea Newswire)--Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced that the District Court for the District of Delaware has granted Parse’s Motion for Summary Judgment of Invalidity for Scale Biosciences’ 11,634,752 patent. The Court concluded that the claims of the ‘752 patent were invalid for lack of written description and lack of enablement’. About Parse Biosciences Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. With technology developed at The University of Washington by co-founders Alex Rosenberg and Charles Roco, Parse has raised over $100 million in capital and is now used by over 3,000 customers across the world. Its growing portfolio of products includes Evercode Whole Transcriptome, Evercode TCR, Evercode BCR, CRISPR Detect, Gene Select, and an interactive data analysis solution, Trailmaker. Parse Biosciences is based in Seattle’s vibrant South Lake Union district, where it recently expanded into a new headquarters and state-of-the-art laboratory. To learn more, please visit https://www.parsebiosciences.com/. View source version on businesswire.com: https://www.businesswire.com/news/home/20251009983648/en/ Website: https://www.parsebiosciences.com/ Contact Parse Biosciences Kaitie Kramer kkramer@parsebiosciences.com This news is a press release provided by Parse Biosciences. Parse Biosciences News Releases 파스 바이오사이언스, 스케일 바이오사이언스 특허 무효화 소송 승소 접근 가능하고 확장 가능한 단일 세포 시퀀싱 솔루션의 선도적 제공업체인 파스 바이오사이언스(Parse Biosciences) 는 델라웨어 지방법원이 스케일 바이오사이언스(Scale Biosciences, 현 10x 지노믹스(10x Genomics))의 11,634,752 특허에 대한 파스의 무효 약식 판결(Summary Judgment of Invalidity) 신청.. 개인회생신청 . 11:40 Tempus Joins Parse Biosciences’ Certified Service Provider Network Parse Biosciences , the leader in scalable and accessible single cell sequencing, is pleased to welcome Tempus as the newest member of its Certified Service Provider (CSP) Program. Together, the companies will broaden access to high-quality and scalable single cell and empower Tempus to... 10월 10일 16:55 More News Health Biotechnology Lawsuit Overseas Parse Biosciences  Follow News Releases  RSS Feed  Website 

개인회생신청